Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 2:33 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2209–2232 of 3,534 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Saline (Placebo Control) Clear all

Conditions: Healthy
Interventions: HAI-05 Influenza Vaccine, Saline; Biological · Other
Lead sponsor: Fraunhofer, Center for Molecular Biotechnology; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 2
States / cities: Wichita, Kansas • Kansas City, Missouri

Conditions: Lumbar Post-Laminectomy Syndrome, Chronic Low Back Pain, Vertebral Compression Fracture, Failed Back Surgery Syndrome
Interventions: Continuous intrathecal prognostic infusion test, Bupivacaine, Fentanyl, Placebo, Intrathecal Drug Delivery System (IDDS); Other · Drug · Device
Lead sponsor: University Hospitals Cleveland Medical Center; Other
Eligibility: 30 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Type1diabetes, Hypoglycemia, Hypoglycemia Unawareness, Islet Cell Transplantation
Interventions: Phentolamine, Propranolol, Placebo; Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 21 Years to 65 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2025
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Functional Iron Deficiency, Trauma, Anemia
Interventions: Iron sucrose, Oxandrolone, IV iron placebo, Oxandrolone placebo; Drug
Lead sponsor: Denver Health and Hospital Authority; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Denver, Colorado

Conditions: Ureteral Stent Placement, Kidney Stone
Interventions: Ketorolac Trometamol 30Mg/1mL Injection, Normal saline; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2027
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Healthy
Interventions: MGN-Placebo, Placebo-MGN; Drug
Lead sponsor: Mologen AG; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: West Bend, Wisconsin

Conditions: Moderate or Severe Submental Fullness
Interventions: Deoxycholic acid injection, Placebo; Drug
Lead sponsor: Kythera Biopharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 506 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 31
States / cities: Birmingham, Alabama • Beverly Hills, California • Irvine, California + 24 more

Conditions: Hypofibrinogenemia, Afibrinogenemia, Bleeding Disorders
Interventions: RiaStAP, Saline; Drug
Lead sponsor: Nicklaus Children's Hospital f/k/a Miami Children's Hospital; Other
Eligibility: 1 Day to 1 Year
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 2
States / cities: Miami, Florida

Conditions: Sinus Infection, Acute Sinusitis
Interventions: amoxicillin/clavulanate potassium, Placebo, Budesonide nasal spray; Drug
Lead sponsor: Daniel Merenstein; Other
Eligibility: 18 Years to 75 Years
Enrollment: 3,720 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 7
States / cities: Los Angeles, California • Washington D.C., District of Columbia • Hyattsville, Maryland + 4 more

Conditions: COVID-19
Interventions: N-803, Saline; Biological · Other
Lead sponsor: ImmunityBio, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 1
States / cities: Lynwood, California

Conditions: Adolescent Idiopathic Scoliosis
Interventions: Tranexamic Acid, Placebo; Drug
Lead sponsor: Boston Children's Hospital; Other
Eligibility: 10 Years to 21 Years
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Acute Kidney Injury
Interventions: Digoxin Antibodies Fab Fragments, Placebo, Baseline EO > 360 pM, EO < 360 pM; Drug · Other · Diagnostic Test
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years and older
Enrollment: 267 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 2
States / cities: Baltimore, Maryland

Conditions: Vancomycin-Resistant Enterococcal Colonization
Interventions: VRELysin™, Placebo; Biological · Other
Lead sponsor: Intralytix, Inc.; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Overactive Bladder
Interventions: onaBoNT-A, Oxybutynin ER; Drug
Lead sponsor: Christopher Patrick Smith; Other
Eligibility: 18 Years to 80 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 2
States / cities: Houston, Texas

Conditions: Pelvic Organ Prolapse
Interventions: Platelet rich plasma (PRP) Injection, Placebo; Procedure
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years and older · Female only
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Healthy Volunteers
Interventions: Norditropin, Placebo; Drug
Lead sponsor: National Institute on Aging (NIA); NIH
Eligibility: 25 Years to 50 Years · Male only
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2014
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Primary Hyperoxaluria Type 1 (PH1), Primary Hyperoxaluria Type 2 (PH2), Kidney Diseases, Urologic Diseases, Genetic Disease
Interventions: DCR-PHXC, Sterile Normal Saline (0.9% NaCl); Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 6 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 5
States / cities: San Francisco, California • Boston, Massachusetts • Rochester, Minnesota + 2 more

Conditions: Acute Pain
Interventions: IV acetaminophen, IV placebo, hydromorphone; Drug
Lead sponsor: Albert Einstein College of Medicine; Other
Eligibility: 21 Years to 64 Years
Enrollment: 162 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Herpes Zoster, Vaccine-Preventable Diseases
Interventions: Low Dose Recombinant Herpes Zoster Vaccine (LZ901), High Dose Recombinant Herpes Zoster Vaccine (LZ901), Placebo; Biological · Drug
Lead sponsor: Beijing Luzhu Biotechnology Co., Ltd.; Other
Eligibility: 50 Years to 70 Years
Enrollment: 66 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Secaucus, New Jersey

Conditions: Sleep Deprivation, Delirium
Interventions: Dexmedetomidine, Placebo; Drug · Other
Lead sponsor: Maisonneuve-Rosemont Hospital; Other
Eligibility: 18 Years to 80 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Transthyretin Amyloidosis With Cardiomyopathy
Interventions: Nucresiran, Sterile Normal Saline (0.9% NaCl); Drug
Lead sponsor: Alnylam Pharmaceuticals; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 1,750 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2032
U.S. locations: 45
States / cities: La Jolla, California • Laguna Hills, California • Stanford, California + 38 more

Conditions: Post Operative Pain, Impacted Third Molar Tooth, Muscle Pain
Interventions: Temporo-masseteric Nerve Block Injection, Oral Pain Medications only; Drug
Lead sponsor: Rutgers, The State University of New Jersey; Other
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Newark, New Jersey

Conditions: Hypotension, Spinal Cord Injury
Interventions: N-Nitro L-arginine-methylester (L-NAME), Head-up Tilt maneuver; Drug · Procedure
Lead sponsor: US Department of Veterans Affairs; Federal
Eligibility: 18 Years to 65 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003 – 2010
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Pulmonary Embolism, Thrombotic Disease
Interventions: DS-1040b, Placebo, Enoxaparin; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 134 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 15
States / cities: Mobile, Alabama • Beverly Hills, California • San Diego, California + 12 more

Search by objective public record fields.

Safety and Immunogenicity Of A Recombinant H5N1 Vaccine In Adults

Determining the Prognostic Value of Continuous Intrathecal Infusion

Adrenergic System in Islet Transplantation

RCT of Goal-directed Iron Supplementation of Anemic, Critically Ill Trauma Patients, With and Without Oxandrolone

NSAIDs Stent Study

A Phase I Study to Assess Cardiac and General Safety and Pharmacokinetics of 60 mg MGN1703

Phase 3 Study of Deoxycholic Acid Injection (ATX-101) Versus Placebo for the Reduction of Localized Subcutaneous Fat in the Submental Area

Human Fibrinogen Concentrate in Pediatric Cardiac Surgery

Nasal Steroids, Irrigation, Oral Antibiotics, and Subgroup Targeting for Effective Management of Acute Sinusitis

Study of the Safety of Therapeutic Treatment With an Immunomodulatory Agent (N-803) in Adults With COVID-19

Does Tranexamic Acid Decrease Blood Loss in Pediatric Idiopathic Scoliosis Surgery?

Preop Digifab in CABG to Reduce Ouabain Levels and Prevent AKI

Safety and Efficacy of Oral Administration of the Phage Cocktail, VRELysin™, In Healthy and VRE-Colonized Subjects

OnabotulinumtoxinA (onaBoNT-A) Versus Oral Oxybutynin ER

Platelet Rich Plasma as an Adjunct Therapy at the Time of Transvaginal Native Tissue Prolapse Surgery

Growth Hormone Administration and the Human Immune System

A Study to Evaluate DCR-PHXC in Children and Adults With Primary Hyperoxaluria Type 1 and Primary Hyperoxaluria Type 2

IV Acetaminophen as Adjuvant Analgesic to Hydromorphone - Emergency Department Patients

A Study to Evaluate Safety and Tolerability of a Recombinant Herpes Zoster Vaccine

Does Nightly Dexmedetomidine Improve Sleep and Reduce Delirium in ICU Patients?

TRITON-CM: A Study to Evaluate Nucresiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy

Jaw Muscle Pain Post Wisdom Molar Surgery

Prevention of Low Blood Pressure in Persons With Tetraplegia

Study to Assess the Safety, Pharmacokinetics/Dynamics of DS-1040b in Subjects With Acute Submassive Pulmonary Embolism